HFNC对成人重症肺炎合并呼吸衰竭患者血气指标、炎症因子和病情的影响

doi:10.3760/cma.j.issn.1007-1245.2024.16.017

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (16): 2718-2723.DOI: 10.3760/cma.j.issn.1007-1245.2024.16.017

HFNC对成人重症肺炎合并呼吸衰竭患者血气指标、炎症因子和病情的影响

邢小艳贺小龙刘力瑞

延安市中医医院重症医学科，延安　716000

收稿日期:2023-12-25 出版日期:2024-08-15 发布日期:2024-09-04
通讯作者: 刘力瑞，Email：86768402@qq.com
基金资助:
目的　探讨经鼻高流量氧疗（high-flow nasal cannula，HFNC）对成人重症肺炎合并呼吸衰竭患者的血气指标、炎症因子和病情的影响，并与无创正压通气（noninvasive positive pressure ventilation，NIPPV）的疗效进行比较。方法　回顾性分析2021年1月至2023年10月期间延安市中医医院95例成人重症肺炎合并呼吸衰竭患者。接受NIPPV治疗的45例患者作为对照组，接受HFNC治疗的50例患者作为观察组。观察组男28例，女22例，年龄（63.64±4.31）岁；对照组男24例，女21例，年龄（64.38±4.57）岁。比较两组患者治疗前及治疗1周后的血气指标［动脉血氧分压（PaO₂）、动脉血二氧化碳分压（PaCO₂）、血氧饱和度（SaO₂）］、呼吸频率（RR）、痰液黏稠度、炎症因子［肿瘤坏死因子（TNF）-α、白细胞介素（IL）-6、高迁移率族蛋白B1（HMGB-1）、高敏C反应蛋白（hs-CRP）和可溶性髓样细胞触发受体（sTREM）］、病情变化［Borg分级量表以及肺炎严重指数（PSI）评分］及治疗效果、并发症。采用独立样本t检验、χ²检验。结果　治疗后，观察组PaO₂、RR、PaCO₂和SaO₂分别为（92.19±5.76）mmHg（1 mmHg=0.133 kPa）、（20.71±2.81）次/min、（45.99±5.33）mmHg、（93.30±9.39）%，对照组分别为（82.99±6.33）mmHg、（23.68±2.96）次/min、（48.19±5.76）mmHg、（83.50±9.43）%，两组差异均有统计学意义（均P<0.05）。观察组治疗后痰液黏稠度低于对照组（P=0.017）。观察组患者治疗后炎症因子水平较治疗前下降，且与对照组相比差异均有统计学意义［治疗后观察组TNF-α、IL-6、HMGB-1、hs-CRP和sTREM水平分别为（17.83±5.70）mg/L、（19.46±5.47）ng/L、（113.05±28.36）μg/L、（33.23±4.08）mg/L、（15.95±2.68）ng/L，对照组分别为（32.02±7.44）mg/L、（33.50±5.62）ng/L、（216.46±25.11）μg/L、（53.91±6.14）mg/L、（35.89±4.49）ng/L］（均P<0.001）。治疗后，观察组Borg指数和PSI评分分别为（3.48±0.39）、（67.99±7.82）分，均低于对照组的（4.34±0.48）、（78.97±8.98）分，差异均有统计学意义（均P<0.001）。观察组撤机时间、住院时间、呼吸困难缓解时间、肺啰音消失时间分别为（3.63±0.72）、（7.75±1.16）、（1.04±0.36）、（4.32±0.77）d，均短于对照组的（4.75±0.85）、（8.46±1.33）、（1.64±0.51）、（5.88±1.06）d，差异均有统计学意义（均P<0.05）。两组患者并发症总发生率差异无统计学意义（P>0.05）。结论　HFNC治疗对成人重症肺炎合并呼吸衰竭患者具有积极的疗效，能够有效改善血气指标、炎症因子和降低痰液黏稠度，促进病情恢复。

Effect of high-flow nasal cannula on blood gas parameters, inflammatory markers, and clinical conditions in adult patients with severe pneumonia and respiratory failure

Xing Xiaoyan, He Xiaolong, Liu Lirui

Department of Critical Care Medicine, Yan'an Hospital of Traditional Chinese Medicine, Yan'an 716000, China

Received:2023-12-25 Online:2024-08-15 Published:2024-09-04
Contact: Liu Lirui, Email: 86768402@qq.com
Supported by:
Objective　 To investigate the effects of high-flow nasal cannula (HFNC) on blood gas parameters, inflammatory markers, and clinical conditions in adult patients with severe pneumonia and respiratory failure, and compare the efficacy of noninvasive positive pressure ventilation (NIPPV) with it. Methods　A retrospective analysis was performed on 95 adult patients with severe pneumonia and respiratory failure treated in Yan'an Hospital of Traditional Chinese Medicine from January 2021 to October 2023. Forty-five patients who received NIPPV were assigned to the control group, and 50 patients who underwent HFNC treatment were assigned to the observation group. In the observation group, there were 28 males and 22 females, aged (63.64±4.31) years. In the control group, there were 24 males and 21 females, aged (64.38±4.57) years. The two groups were compared in terms of blood gas parameters [arterial partial pressure of oxygen (PaO₂), arterial partial pressure of carbon dioxide (PaCO₂), and oxygen saturation (SaO₂)], respiratory rate (RR), sputum viscosity, inflammatory markers [tumor necrosis factor (TNF)-α, interleukin (IL)-6, high mobility group protein B1 (HMGB-1), high-sensitivity C-reactive protein (hs-CRP), and soluble myeloid cell trigger receptor (sTREM)], and changes in condition [Borg scale and Pneumonia Severity Index (PSI) scores] before treatment and 1 week after treatment, treatment efficiency, and complications. Independent sample t test and χ² test were used. Results　After treatment, the PaO₂, RR, PaCO₂, and SaO₂ in the observation group were (92.19±5.76) mmHg (1 mmHg = 0.133 kPa), (20.71±2.81) times/min, (45.99±5.33) mmHg, and (93.30±9.39)%, those in the control group were (82.99±6.33) mmHg, (23.68±2.96) times/min, (48.19±5.76) mmHg, and (83.50±9.43)%, with statistically significant differences between the two groups (all P<0.05). The phlegm viscosity of the observation group was lower than that of the control group after treatment (P=0.017). The levels of inflammatory factors in the observation group decreased after treatment compared with those before treatment, and there were statistically significant differences compared with those in the control group [the levels of TNF-α, IL-6, HMGB-1, hs-CRP, and sTREM in the observation group were (17.83±5.70) mg/L, (19.46±5.47) ng/L, (113.05±28.36) μg/L, (33.23±4.08) mg/L, and (15.95±2.68) ng/L, and those in the control group were (32.02±7.44) mg/L, (33.50±5.62) ng/L, (216.46±25.11) μg/L, (53.91±6.14) mg/L, and(35.89±4.49) ng/L] (all P<0.001). After treatment, the Borg index and PSI scores of the observation group were (3.48±0.39) and (67.99±7.82) points, which were lower than those of the control group [(4.34±0.48) and (78.97±8.98) points], with statistically significant differences (both P<0.001). The weaning time, hospital stay, dyspnea relief time, and disappearance time of pulmonary rales in the observation group were (3.63±0.72), (7.75±1.16), (1.04±0.36), and (4.32±0.77) d, which were shorter than those in the control group [(4.75±0.85), (8.46±1.33), (1.64±0.51), and (5.88±1.06) d], with statistically significant differences (all P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups (P>0.05). Conclusion　HFNC therapy has a positive effect on adult patients with severe pneumonia and respiratory failure, effectively improving blood gas parameters, reducing inflammatory markers, and decreasing sputum viscosity, thus facilitating recovery.

摘要/Abstract

摘要：

目的　探讨经鼻高流量氧疗（high-flow nasal cannula，HFNC）对成人重症肺炎合并呼吸衰竭患者的血气指标、炎症因子和病情的影响，并与无创正压通气（noninvasive positive pressure ventilation，NIPPV）的疗效进行比较。方法　回顾性分析2021年1月至2023年10月期间延安市中医医院95例成人重症肺炎合并呼吸衰竭患者。接受NIPPV治疗的45例患者作为对照组，接受HFNC治疗的50例患者作为观察组。观察组男28例，女22例，年龄（63.64±4.31）岁；对照组男24例，女21例，年龄（64.38±4.57）岁。比较两组患者治疗前及治疗1周后的血气指标［动脉血氧分压（PaO₂）、动脉血二氧化碳分压（PaCO₂）、血氧饱和度（SaO₂）］、呼吸频率（RR）、痰液黏稠度、炎症因子［肿瘤坏死因子（TNF）-α、白细胞介素（IL）-6、高迁移率族蛋白B1（HMGB-1）、高敏C反应蛋白（hs-CRP）和可溶性髓样细胞触发受体（sTREM）］、病情变化［Borg分级量表以及肺炎严重指数（PSI）评分］及治疗效果、并发症。采用独立样本t检验、χ²检验。结果　治疗后，观察组PaO₂、RR、PaCO₂和SaO₂分别为（92.19±5.76）mmHg（1 mmHg=0.133 kPa）、（20.71±2.81）次/min、（45.99±5.33）mmHg、（93.30±9.39）%，对照组分别为（82.99±6.33）mmHg、（23.68±2.96）次/min、（48.19±5.76）mmHg、（83.50±9.43）%，两组差异均有统计学意义（均P<0.05）。观察组治疗后痰液黏稠度低于对照组（P=0.017）。观察组患者治疗后炎症因子水平较治疗前下降，且与对照组相比差异均有统计学意义［治疗后观察组TNF-α、IL-6、HMGB-1、hs-CRP和sTREM水平分别为（17.83±5.70）mg/L、（19.46±5.47）ng/L、（113.05±28.36）μg/L、（33.23±4.08）mg/L、（15.95±2.68）ng/L，对照组分别为（32.02±7.44）mg/L、（33.50±5.62）ng/L、（216.46±25.11）μg/L、（53.91±6.14）mg/L、（35.89±4.49）ng/L］（均P<0.001）。治疗后，观察组Borg指数和PSI评分分别为（3.48±0.39）、（67.99±7.82）分，均低于对照组的（4.34±0.48）、（78.97±8.98）分，差异均有统计学意义（均P<0.001）。观察组撤机时间、住院时间、呼吸困难缓解时间、肺啰音消失时间分别为（3.63±0.72）、（7.75±1.16）、（1.04±0.36）、（4.32±0.77）d，均短于对照组的（4.75±0.85）、（8.46±1.33）、（1.64±0.51）、（5.88±1.06）d，差异均有统计学意义（均P<0.05）。两组患者并发症总发生率差异无统计学意义（P>0.05）。结论　HFNC治疗对成人重症肺炎合并呼吸衰竭患者具有积极的疗效，能够有效改善血气指标、炎症因子和降低痰液黏稠度，促进病情恢复。

关键词:

重症肺炎, 呼吸衰竭, 经鼻高流量氧疗, 无创正压通气, 血气指标

Abstract:

Objective　 To investigate the effects of high-flow nasal cannula (HFNC) on blood gas parameters, inflammatory markers, and clinical conditions in adult patients with severe pneumonia and respiratory failure, and compare the efficacy of noninvasive positive pressure ventilation (NIPPV) with it. Methods　A retrospective analysis was performed on 95 adult patients with severe pneumonia and respiratory failure treated in Yan'an Hospital of Traditional Chinese Medicine from January 2021 to October 2023. Forty-five patients who received NIPPV were assigned to the control group, and 50 patients who underwent HFNC treatment were assigned to the observation group. In the observation group, there were 28 males and 22 females, aged (63.64±4.31) years. In the control group, there were 24 males and 21 females, aged (64.38±4.57) years. The two groups were compared in terms of blood gas parameters [arterial partial pressure of oxygen (PaO₂), arterial partial pressure of carbon dioxide (PaCO₂), and oxygen saturation (SaO₂)], respiratory rate (RR), sputum viscosity, inflammatory markers [tumor necrosis factor (TNF)-α, interleukin (IL)-6, high mobility group protein B1 (HMGB-1), high-sensitivity C-reactive protein (hs-CRP), and soluble myeloid cell trigger receptor (sTREM)], and changes in condition [Borg scale and Pneumonia Severity Index (PSI) scores] before treatment and 1 week after treatment, treatment efficiency, and complications. Independent sample t test and χ² test were used. Results　After treatment, the PaO₂, RR, PaCO₂, and SaO₂ in the observation group were (92.19±5.76) mmHg (1 mmHg = 0.133 kPa), (20.71±2.81) times/min, (45.99±5.33) mmHg, and (93.30±9.39)%, those in the control group were (82.99±6.33) mmHg, (23.68±2.96) times/min, (48.19±5.76) mmHg, and (83.50±9.43)%, with statistically significant differences between the two groups (all P<0.05). The phlegm viscosity of the observation group was lower than that of the control group after treatment (P=0.017). The levels of inflammatory factors in the observation group decreased after treatment compared with those before treatment, and there were statistically significant differences compared with those in the control group [the levels of TNF-α, IL-6, HMGB-1, hs-CRP, and sTREM in the observation group were (17.83±5.70) mg/L, (19.46±5.47) ng/L, (113.05±28.36) μg/L, (33.23±4.08) mg/L, and (15.95±2.68) ng/L, and those in the control group were (32.02±7.44) mg/L, (33.50±5.62) ng/L, (216.46±25.11) μg/L, (53.91±6.14) mg/L, and(35.89±4.49) ng/L] (all P<0.001). After treatment, the Borg index and PSI scores of the observation group were (3.48±0.39) and (67.99±7.82) points, which were lower than those of the control group [(4.34±0.48) and (78.97±8.98) points], with statistically significant differences (both P<0.001). The weaning time, hospital stay, dyspnea relief time, and disappearance time of pulmonary rales in the observation group were (3.63±0.72), (7.75±1.16), (1.04±0.36), and (4.32±0.77) d, which were shorter than those in the control group [(4.75±0.85), (8.46±1.33), (1.64±0.51), and (5.88±1.06) d], with statistically significant differences (all P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups (P>0.05). Conclusion　HFNC therapy has a positive effect on adult patients with severe pneumonia and respiratory failure, effectively improving blood gas parameters, reducing inflammatory markers, and decreasing sputum viscosity, thus facilitating recovery.

Key words:

Severe pneumonia, Respiratory failure, High-flow nasal cannula, Noninvasive positive pressure ventilation, Blood gas parameters

邢小艳贺小龙刘力瑞.

HFNC对成人重症肺炎合并呼吸衰竭患者血气指标、炎症因子和病情的影响 [J]. 国际医药卫生导报, 2024, 30(16): 2718-2723.

Xing Xiaoyan, He Xiaolong, Liu Lirui.

Effect of high-flow nasal cannula on blood gas parameters, inflammatory markers, and clinical conditions in adult patients with severe pneumonia and respiratory failure [J]. International Medicine and Health Guidance News, 2024, 30(16): 2718-2723.

参考文献

[1] 韩振坤,尹彦斌,姜素文,等.血清Ang-2和PGRN与老年重症肺炎合并呼吸衰竭患者预后的关系[J].中国现代医学杂志,2021,31(21):91-97. DOI:10.3969/j.issn.1005-8982.2021. 21.015.
[2] Fisher K, Trupka T, Micek ST, et al. A prospective one-year microbiologic survey of combined pneumonia and respiratory failure[J]. Surg Infect (Larchmt), 2017, 18(7):827-833. DOI: 10.1089/sur.2017.111.
[3] 徐亚琴,蔡珣,王圆圆.经鼻高流量湿化氧疗与无创正压通气治疗AECOPD并发呼吸衰竭对血气分析指标及氧化应激的影响[J].海军医学杂志,2022,43(4):380-384,405. DOI:10.3969/j.issn.1009-0754.2022.04.009.
[4] 王健,马新华,李莉,等.经鼻高流量氧疗治疗Ⅰ型呼吸衰竭的疗效分析[J].中国现代医学杂志,2018,28(14):65-70. DOI:10.3969/j.issn.1005-8982.2018.014.013.
[5] 中华医学会呼吸病学分会感染学组.中国成人医院获得性肺炎与呼吸机相关性肺炎诊断和治疗指南(2018年版)[J].中华结核和呼吸杂志,2018,41(4):255-280. DOI:10.3760/cma.j.issn.1001-0939.2018.04.006.
[6] 中华医学会呼吸病学分会呼吸危重症医学学组,中国医师协会呼吸医师分会危重症医学工作委员会.成人经鼻高流量湿化氧疗临床规范应用专家共识[J].中华结核和呼吸杂志,2019,42(2):83-91. DOI:10.3760/cma.j.issn.1001-0939. 2019.02.003.
[7] 刘巧艳,王娟,王萍,等.仰俯卧位机械通气对重症肺炎合并呼吸衰竭患者肺功能及炎症因子水平的影响[J].医学临床研究,2023,40(9):1315-1318,1323. DOI:10.3969/j.issn.1671-7171.2023.09.010.
[8] 朱敏,丁晓芳.营养干预辅助持续正压通气对肺炎合并呼吸衰竭早产儿血气水平及患儿预后的影响[J].海军医学杂志,2021,42(5):606-609. DOI:10.3969/j.issn.1009-0754. 2021.05.021.
[9] 司艳,张娜娜.老年COPD合并Ⅱ型呼吸衰竭患者气管切开术后采用序贯经鼻高流量加温湿化氧疗对患者呼吸道感染及临床结局的影响[J].医学临床研究,2023,40(5):706-709. DOI:10.3969/j.issn.1671-7171.2023.05.019.
[10] Ding L, Wang L, Ma W, et al. Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study[J]. Crit Care, 2020, 24(1):28. DOI: 10.1186/s13054-020-2738-5.
[11] 涂秀华,雷妹,陈彦清,等. 预防性使用经鼻高流量湿化氧疗可减少老年非小细胞肺癌患者术后肺部并发症发生:倾向性评分匹配研究[J/OL].中国胸心血管外科临床杂志,1-7[2024-02-04]. http://kns.cnki.net/kcms/detail/51.1492.R.20230718.1640.004.html.
[12] 李童,刘卫东,韩宏月,等.高流量湿化氧疗的临床应用研究进展[J].国际麻醉学与复苏杂志,2023,44(4):411-415. DOI:10.3760/cma.j.cn321761-20221114-00782.
[13] Rochwerg B, Einav S, Chaudhuri D, et al. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline[J]. Intensive Care Med, 2020, 46(12):2226-2237. DOI: 10.1007/s00134-020- 06312-y.
[14] 谢波,高颖.经鼻高流量湿化氧疗联合肺泡灌洗治疗重症肺炎合并呼吸衰竭患者疗效观察[J].陕西医学杂志,2023,52(1):49-52. DOI:10.3969/j.issn.1000-7377.2023.01.011.
[15] 张国英,王静,王传霞,等.经鼻高流量湿化氧疗对急性心源性肺水肿患者的临床疗效[J].山东大学学报(医学版),2020,58(1):77-80,86.
[16] 赵红玲,梁金排,刘淑红,等.HFNC技术治疗老年慢性阻塞性肺疾病合并轻型Ⅱ型呼吸衰竭的效果[J].中国老年学杂志,2023,43(16):3908-3911. DOI:10.3969/j.issn.1005-9202. 2023.16.020.
[17] 方杏香,陆丹琼,王颖,等.CPAP辅助治疗重症肺炎合并呼吸衰竭患儿预后影响因素分析及对策[J].中国妇幼保健,2021,36(23):5522-5525. DOI:10.19829/j.zgfybj.issn.1001-4411.2021.23.048.
[18] 王珂,陈丽勤,何萍.经鼻高流量湿化氧疗系统在开胸术后急性低氧性呼吸衰竭患者中的应用及研究[J].重庆医科大学学报,2020,45(11):1579-1582. DOI:10.13406/j.cnki.cyxb.002326.
[19] 林颖康,李晓倩,陈静,等.慢性阻塞性肺疾病急性加重患者撤机后序贯使用经鼻高流量氧疗对比无创正压通气临床疗效的Meta分析[J].中国呼吸与危重监护杂志,2023,22(10):727-735. DOI:10.7507/1671-6205.202304031.
[20] 杨福勋,罗小秀,王兰,等.经鼻高流量氧疗与无创正压通气对急性低氧性呼吸衰竭患者无痛纤维支气管镜检查术呼吸支持疗效的比较[J].中国实用内科杂志,2021,41(9):804-808. DOI:10.19538/j.nk2021090111.
[21] Huang Y, Lei W, Zhang W, et al. High-flow nasal cannula in hypercapnic respiratory failure: a systematic review and meta-analysis[J]. Can Respir J, 2020, 2020:7406457. DOI: 10.1155/2020/7406457.
[22] 石买雄.有创—无创序贯机械通气在95例重症肺炎合并呼吸衰竭治疗中的效果观察[J].贵州医药,2019,43(11):1718-1720. DOI:10.3969/j.issn.1000-744X.2019.11.011.
[23] 中国医师协会急诊医师分会,中华医学会急诊医学分会,中国急诊专科医联体,等.急诊成人经鼻高流量氧疗临床应用专家共识[J].中华急诊医学杂志,2021,30(9):1041-1050. DOI:10.3760/cma.j.issn.1671-0282.2021.09.001.
[24] Kim BK, Kim S, Kim CY, et al. Factors associated with failure of high-flow nasal cannula[J]. Respir Care, 2020, 65(9):1276-1284. DOI: 10.4187/respcare.07403.
[25] 王国玉,胡舒环,王浩宇,等.老年下呼吸道感染的病原学特征及经鼻高流量湿化氧疗辅助的疗效分析[J].中国现代医学杂志,2023,33(22):58-63. DOI:10.3969/j.issn.1005- 8982.2023.22.011.
[26] Rochwerg B, Granton D, Wang DX, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis[J]. Intensive Care Med, 2019, 45(5):563-572. DOI: 10.1007/s00134-019-05590-5.
[27] 王翠,施敏骅.经鼻高流量氧疗治疗慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭的临床疗效观察[J].中国呼吸与危重监护杂志,2021,20(11):807-812. DOI:10.7507/1671- 6205.202101041.
[28] 周本昊,姜超,韩云宏,等.经鼻高流量氧疗在基于膈肌浅快呼吸指数评估的高风险脱机患者中的应用[J].南京医科大学学报(自然科学版),2021,41(1):109-113. DOI:10.7655/NYDXBNS20210120.
[29] 张明明,徐娟,钱晓璐,等.高风险脱机患者高流量氧疗与低频持续气道正压通气效果比较[J].护理学杂志,2023,38(10):57-60. DOI:10.3870/j.issn.1001-4152.2023. 10.057.

HFNC对成人重症肺炎合并呼吸衰竭患者血气指标、炎症因子和病情的影响

Effect of high-flow nasal cannula on blood gas parameters, inflammatory markers, and clinical conditions in adult patients with severe pneumonia and respiratory failure

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

编辑推荐

Metrics

[1]	赵竹莉华爱玲高慧梅. 脓毒症合并呼吸衰竭患者初次撤机失败的风险模型构建与验证 [J]. 国际医药卫生导报, 2024, 30(14): 2361-2366.
[2]	刘巧艳王娟王永兴徐永妮王萍肖林萍. 有创无创序贯通气对重症肺炎患者血气分析指标及炎症反应的影响 [J]. 国际医药卫生导报, 2024, 30(10): 1643-1647.
[3]	何炎佳. 早期俯卧位下高流量氧疗在改善重症肺炎相关急性呼吸衰竭中的应用 [J]. 国际医药卫生导报, 2024, 30(1): 72-76.
[4]	宗海燕朱晔. 基于三度空间模型的精细化护理在AECOPD并呼吸衰竭患者中的实践研究 [J]. 国际医药卫生导报, 2024, 30(1): 145-150.
[5]	路秀芳田金静康亚丽. 相关生化指标在AECOPD伴呼吸衰竭患者中的水平变化及临床意义分析 [J]. 国际医药卫生导报, 2023, 29(8): 1131-1134.
[6]	袁法伟李炳奇. 体外膜肺氧合治疗呼吸衰竭的效果及预后分析 [J]. 国际医药卫生导报, 2023, 29(7): 973-977.
[7]	白成芳常钦达. CRP/ALB比值及SIL对吉兰-巴雷综合征患者呼吸衰竭的预测价值 [J]. 国际医药卫生导报, 2023, 29(18): 2580-2584.
[8]	张文凤吴桂敏. 医护一体化管理及精细化气道管理在呼吸道感染患者中的应用价值 [J]. 国际医药卫生导报, 2023, 29(17): 2393-2397.
[9]	潘海萍何平. 示警性预防护理对重症肺炎患者风险系数及临床结局的影响 [J]. 国际医药卫生导报, 2023, 29(17): 2494-2498.
[10]	徐鸿, 李名敏, 孙伟. 慢性阻塞性肺疾病患者应用经鼻高流量湿化氧疗治疗的研究现状[J]. 国际医药卫生导报, 2022, 28(8): 1123-1126.
[11]	吴莹莹江成养郭卫东郭艳芬. 无创正压通气联合洛贝林治疗COPD合并呼吸衰竭的疗效观察[J]. 国际医药卫生导报, 2022, 28(16): 2272-2275.
[12]	袁法伟, 冯辉斌, 尹欢, 郑鲲, 梅喜平, 袁利学, 祝小梅. 呼吸衰竭患者体外膜肺氧合治疗后心率、氧合指数改变及APACHEⅡ与SOFA评分对预后的预测价值[J]. 国际医药卫生导报, 2022, 28(10): 1338-1342.